Trial reportPediatric nephrology (Berlin, Germany)2026
Oral liposomal iron vs. oral iron polymaltose in children with chronic kidney disease iron deficiency anemia: a cross-over study.
Trial report in Pediatric nephrology (Berlin, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLimited data exist on the use of novel iron therapies in children with chronic kidney disease (CKD). We conducted a cross-over study to compare iron polymaltose complex (IPC) and liposomal iron in pediatric patients with CKD and iron deficiency anemia (IDA).
methodsCross-over study of 33 children with CKD and IDA was conducted. They were randomized into 2 groups (group A: 17 patients, group B: 16 patients) to receive either liposomal iron or IPC for 3 months. After an 8-week washout period, they were switched to the other therapy. Red cell and iron indices, as well as bone minerals and 25(OH)D
resultsHb levels increased by at least 1 g/dL in 48% following liposomal iron therapy and 51.5% following IPC therapy. There was no statistically significant difference in ΔHb, ΔFe, ΔsTR (transferrin receptor), or ΔTSAT (transferrin saturation) levels between the groups (p > 0.05). By mixed model analysis, IPC showed a higher Hb and TSAT and lower TRresponse compared with liposomal iron. IPC, but not liposomal iron, led to a significant reduction in serum phosphorus in both groups. Thirty-six percent of IPC recipients experienced adverse effects, compared to 3% of liposomal iron recipients.
conclusionsBoth IPC and liposomal iron effectively improved iron status in children with CKD and IDA. However, IPC indicated a superior response, whereas liposomal iron was associated with a more favorable tolerability profile.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.